Lin Hong-Han, Tsai Wen-Chiuan, Tsai Chia-Kuang, Chen Ssu-Han, Huang Li-Chun, Hueng Dueng-Yuan, Hung Kuang-Chen
Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Chenggong Rd., Neihu, Taipei, 11490, Taiwan.
Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, 11490, Taiwan.
J Mol Neurosci. 2021 Aug;71(8):1614-1621. doi: 10.1007/s12031-021-01806-w. Epub 2021 Feb 27.
Solute carrier family 16 member 1 (SLC16A1) is a crucial transcription factor in modifying cancer progression and metastasis. However, its character in defining the clinical prognosis of human gliomas has not been illuminated. In our analysis from PREdiction of Clinical Outcomes from Genomic Profiles (PRECOG), The Cancer Genome Atlas (TCGA), and Chinese Glioma Genome Atlas (CGGA), we found that SLC16A1 mRNA expression level was significantly increased in high-grade gliomas in contrast to low-grade gliomas and non-tumor controls (P < 0.05). Kaplan-Meier analysis of four independent cohort studies from the Gene Expression Omnibus (GEO) profile, TCGA, and CGGA which consistently presented patients with high SLC16A1 mRNA expression displayed poor overall survival in high-grade glioma patients (P < 0.05 by log-rank test). Based on the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), the protein-protein interaction analysis of SLC16A1-regulated oncogenesis showed SLC16A1 as a potential hub protein. Immunohistochemical staining exhibited that SLC16A1 protein overexpressed in high-grade gliomas compared with low-grade clinical glioma samples. All these findings suggest that SLC16A1 expression has a positive correlation with WHO pathological grading and poor survival. SLC16A1 might be a potential biomarker of prognosis in human gliomas.
溶质载体家族16成员1（SLC16A1）是一种在调节癌症进展和转移中起关键作用的转录因子。然而，其在界定人类胶质瘤临床预后方面的特征尚未阐明。在我们对来自基因组图谱临床结果预测（PRECOG）、癌症基因组图谱（TCGA）和中国胶质瘤基因组图谱（CGGA）的分析中，我们发现与低级别胶质瘤和非肿瘤对照相比，高级别胶质瘤中SLC16A1 mRNA表达水平显著升高（P < 0.05）。对来自基因表达综合数据库（GEO）图谱、TCGA和CGGA的四项独立队列研究进行的Kaplan-Meier分析一致显示，SLC16A1 mRNA表达高的患者在高级别胶质瘤患者中总体生存率较差（对数秩检验P < 0.05）。基于蛋白质相互作用网络搜索工具（STRING），对SLC16A1调节的肿瘤发生进行的蛋白质-蛋白质相互作用分析显示SLC16A1是一种潜在的枢纽蛋白。免疫组织化学染色显示，与低级别临床胶质瘤样本相比，高级别胶质瘤中SLC16A1蛋白过表达。所有这些发现表明，SLC16A1表达与世界卫生组织病理分级呈正相关且生存较差。SLC16A1可能是人类胶质瘤预后的潜在生物标志物。
